Download Sample
Schedule a Meeting
NA : +1 804 441 9344
sales@towardshealthcare.com
August 2025
The global cardiac safety services market size reached USD 824.35 million in 2024, grew to USD 919.57 million in 2025, and is projected to hit around USD 2459.29 million by 2034, expanding at a CAGR of 11.55% during the forecast period from 2025 to 2034.
The cardiac healthcare services and solutions remain the topmost priority of several government organizations and the leading industries in cardiac care. Some of the prominent cardiac healthcare providers and supporters include the American Heart Association, the European Commission, and the Asia-Pacific Cardiovascular Disease Association.
Moreover, the major companies providing cardiac care solutions include Boston Scientific, GE Healthcare, Biotronik, Abbott Laboratories, etc. The World Health Organization contributes to enhancing healthcare across cardiology, oncology, neurology, and mental health research and development areas across the globe. With the rising prevalence of cardiovascular disorders, there is an urgent need for groundbreaking innovations in medical devices and safety services to protect the cardiac health of the global population.
| Table | Scope |
| Market Size in 2025 | USD 919.57 Million |
| Projected Market Size in 2034 | USD 2459.29 Million |
| CAGR (2025 - 2034) | 11.55% |
| Leading Region | North America Share 38% |
| Market Segmentation | By Type of Service, By End User, By Phase of Drug Development, By Therapeutic Area, By Region |
| Top Key Players | Bioclinica, Clario, BioTelemetry, Inc., Banook Group, Medpace, Inc., Laboratory Corporation of America Holdings, Celerion, Inc., ICON plc, IQVIA, SGS SA, Parexel International Corporation, Cardiovascular Research Foundation, Richmond Pharmacology, Medtronic plc, Certara, Inc., Biotelemetry Research Services, Apex Medical Research, Covance, Eurofins Scientific, Biofortis Clinical Research |
The cardiac safety services market refers to the specialized segment of clinical research and drug development that focuses on assessing and ensuring the cardiovascular safety profile of pharmaceutical compounds, biologics, and medical devices. These services are critical during preclinical and clinical trial phases to identify, monitor, and mitigate potential cardiac-related adverse effects such as arrhythmias, QT interval prolongation, ischemia, or heart failure before regulatory approval and commercialization. The market includes contract research organizations, specialized cardiac safety labs, and technology providers offering services like ECG analysis, hemodynamic monitoring, and cardiovascular imaging. Growing drug development pipelines, stringent regulatory requirements, and an increasing prevalence of cardiovascular diseases are primary drivers of market growth.
Artificial intelligence and machine learning contribute to enabling precision medicine implementation in cardiovascular research and clinical care. AI plays a pivotal role in heart diseases by prompting its use in clinical applications. These AI-driven clinical tasks are related to cardiac imaging, electrocardiology, mobile and wearable technologies, genetics, continuous bedside monitoring, etc. AI enhances patient safety, improves data protection, and promotes fairness in healthcare systems. AI can work in combination with precision medicine to improve patient outcomes and enhance clinical decision-making.
What are the Various Trends Observed in the Cardiac Safety Services Market?
Cardiac safety services ensure the efficacy and safety of medical and pharmaceutical devices. They assist pharmaceutical companies and regulatory agencies in making informed decisions about drug development and regulatory approval. The U.S. FDA plays a crucial role in regulatory approvals for treatments that reduce the risk of heart problems in adults who are dealing with obesity.
What are the Potential Challenges in the Cardiac Safety Services Market?
There are rising concerns for most people about healthcare costs and the affordability of those services. Patients face challenges in experiencing improved treatment outcomes due to some disparities. There are rising mortality rates due to unexpected cardiovascular health scenarios.
The National Heart, Lung, and Blood Institute is dedicated to coronary heart disease research. It conducts coronary heart disease programs and research that is funded by the NHLBI itself. The national initiative named ‘Million Hearts’ recognized 32 independent practitioners, community health centers, large health systems, and specialty groups as hypertension control champions of 2024. The Million Hearts initiative has set its vision for 2027 to prevent 1 million strokes and heart attacks within 5 years.
The ECG/Holter measurement & analysis services segment dominated the cardiac safety services market in 2024, owing to the importance of these non-invasive tests to assess heart health. The electrocardiogram gives a quick snapshot of heart activity, identifies abnormal heart rhythms, and detects heart attacks. The Holter monitor can continuously monitor heart health and can detect intermittent heart issues. These tests and medical solutions allow personalized treatment plans and offer early diagnosis and prevention of health complications.
The resting ECG analysis sub-segment held the largest revenue share. The resting ECG analysis can potentially monitor the effectiveness of treatments, and it is a simple and convenient non-invasive test to assess heart health. Resting ECGs are helpful in the detection of abnormal heartbeats and the identification of patterns of heart rate.
The continuous ECG telemetry segment is seen to grow rapidly as a sub-segment in the cardiac safety services market during the forecast period due to improved workflow and efficiency offered by this technology. It can improve patient safety, enhance diagnostic capabilities, and enhance patient experience. Telecardiology services are improved by the integration of cloud-based systems and remote monitoring devices.
The pharmaceutical & biopharmaceutical companies segment dominated the cardiac safety services market in 2024, owing to the major role of these companies in patient safety, well-being, early detection of risks, and risk mitigation. A streamlined drug development, regulatory compliance, and efficiency improve the business portfolio in the global market. The leading companies focus on delivering cost-effective solutions and reducing potential risks.
The contract research organizations (CROs) segment is expected to witness the fastest rate of growth in the cardiac safety services market during the predicted timeframe due to increased access to resources and networks and the increased focus on risk mitigation. The regulatory knowledge of cardiovascular medicines raises the standards of CROs. CROs are well-equipped with specialized expertise, enhanced data quality, and data integrity.
The phase III segment dominated the cardiac safety services market in 2024, owing to the significance of phase III clinical trials in the assessment of the cardiac safety of new drugs. They ensure long-term safety and evaluate long-term cardiac effects. Phase III clinical trials can identify specific cardiac risks, and this data can create a strong safety profile. They assist healthcare providers with the safe and proper use of resources in clinical practice.
The phase II segment is expected to witness the fastest rate of growth in the cardiac safety services market during the forecast period due to the potential of phase II clinical trials to detect serious cardiac risks and related adverse events among a large patient population. Phase II trials are effective in adaptive trial designs to understand the benefit-risk profile. They help in the careful monitoring of cardiac function through cardiac imaging, biomarkers, and ECG parameters.
The oncology segment dominated the cardiac safety services market in 2024. This segment led the market due to the potential management of cardiovascular risks arising from cancer treatments. Cardiac safety services play a crucial role in the proactive monitoring of the cardiac health of patients while going through cardio-oncology treatments. Cardio-oncology services can identify patients at high risk of heart issues before starting cancer treatments.
The cardiology segment is expected to witness the fastest rate of growth in the cardiac safety services market during the predicted timeframe due to improved efficiency and cost savings by using cardiac safety services. These cardiac health services majorly help in patient care and management of chronic diseases. Telecardiology results in the expansion of cardiology care by improving the accessibility and convenience of cardiac healthcare.
North America dominated the market share by 38% in 2024, owing to the high prevalence of cardiovascular diseases and stringent regulatory compliance. In July 2025, the American Heart Association organized the ‘Cardiovascular-Kidney-Metabolic Health Initiative’ to improve treatments for those health conditions that lead to heart disease and stroke. For this purpose, the AHA invited several healthcare organizations to enroll in this initiative to spread awareness and enhance screening and treatments for cardiovascular-kidney-metabolic syndrome. People from about 15 regions, including some states, cities, and metro areas, participated in it to gain the benefits of this groundbreaking initiative. Some of these regions include the Atlanta metro, San Diego metro, Ohio, Washington D.C. and Maryland, North Carolina, etc.
Furthermore, the World Heart Federation states that about 80% of premature deaths from cardiovascular diseases can be prevented through enhanced affordability and access to healthcare services and early screening. In December 2024, the American Heart Association introduced remarkable advancements in cardiovascular research for the year 2024. These include a new tool named ‘PREVENT risk calculator’ which has been developed by volunteer science experts who work with the AHA to assist people in better understand their cardiovascular risk.
In April 2025, Roche announced the investment of USD 50 billion in diagnostics and pharmaceuticals in the U.S. over the next 5 years. These investments aim to create 12,000 jobs, out of which 1,000 will be for Roche and more than 11,000 in new manufacturing capabilities in the U.S. Furthermore, in December 2024, Capstan Medical reported an investment of $110 million for a heart valve with a robotic system. In June 2024, Endotronix announced pre-market approval from the U.S. FDA for the Cordella PA sensor system to treat heart failure.
In July 2025, the Government of Canada announced its support, along with the funding of $1.3 billion, for over 9,700 researchers and their research projects across the nation.
Moreover, in June 2025, the Canadian Genomics Strategy (CGS), Genome Canada of the Government of Canada, announced investments in the adoption and commercialization of genomics-driven biotechnology solutions that will tackle urgent challenges in industries and healthcare. For this purpose, over $6 million was funded through Genome Canada and funded through the CGS, while $12 million through the regional genome centers was supported by about five projects.
Asia Pacific is expected to grow at the fastest CAGR in the cardiac safety services market during the forecast period due to the increasing investments in research and development and clinical trials. In October 2024, the Asia-Pacific Cardiovascular Disease Association concluded a summit on cardiovascular disease in the Asia-Pacific in collaboration with the Ministry of Public Health-Department of Medical Services, and the National Health Security Office, Thailand. Digital healthcare plays a major role in the cardiac prevention program in Indonesia and holds an optimistic future. The Asia-Pacific Cardiovascular Disease Alliance focuses on managing heart diseases in Asia.
In May 2025, Philips reported the urgent need for investments in cardiac infrastructure to reduce the burden of cardiovascular diseases for the global population. A Bangalore-based R&D center of Philips is dedicated to developing and providing image-guided therapy and next-generation cardiac solutions. The significant efforts of companies like Philips in India make advanced cardiac treatments more accessible and affordable for the Indian population.
According to China’s Ministry of Commerce, the National Medical Products Administration, and the National Health Commission, China signaled a relaxation of its health industries for international investors to foster China’s economic development. The World Bank’s report with the Chinese government stated that China’s health expenditure is expected to increase to USD 2.5 trillion in 2035, which is up from USD 543.5 billion in 2014. These estimates are in accordance with the Healthy China 2030 initiative to meet rising healthcare costs and set major structural reforms in healthcare.
Europe is expected to grow at a notable rate in the cardiac safety services market in 2024. This regional growth is attributed to the increasing outsourcing of cardiac safety testing services by pharmaceutical and biotechnology companies to well-renowned contract research organizations. The MedTech Europe Cardiovascular Sector Group invited and urged the European Union to adopt the EU cardiovascular health plan, which aims to reduce CVD mortality in Europe by 30% by 2030. In December 2024, the European Commission introduced the EU cardiovascular health plan to foster national and European action towards improving cardiovascular health across Europe.
In March 2025, the Ministry of Labor, Health, Solidarity, and Families published new guidelines for the establishment of a healthcare pricing campaign for 2025 and also stated that France has increased hospital funding in 2025. Moreover, in December 2024, France experienced a transition in healthcare and energy through €700 million in financing from the European Investment Bank and Credit Agricole, which aims to strongly support the French regions. According to the French Healthcare reports, healthcare innovations in France attract global investors.
In July 2024, Susan Hill, vice president of Global Product Management, Digital Products & Solutions at IQVIA, said that the company feels incredibly honored to be recognized by MedTech Breakthrough for IQVIA’s innovation in AI-powered healthcare solutions. She also proclaimed that the insertion of artificial intelligence capabilities within the SmartSolve platform encourages and helps human decision-making for safe and effective care of the global population.
By Type of Service
By End User
By Phase of Drug Development
By Therapeutic Area
By Region
August 2025
August 2025
July 2025
July 2025